Acromegaly and hyperprolactinemia in McCune-Albright syndrome. Evidence of hypothalamic dysfunction.
In a 21-year-old woman with McCune-Albright syndrome, acromegaly and hyperprolactinemia with hypopituitarism developed secondary to a large pituitary tumor. Bromocriptine suppressed the secretion of growth hormone and prolactin, with a reduction in tumor size. However, at the age of 8, she already showed evidence of biochemical acromegaly, with a paradoxical rise of growth hormone levels during two glucose tolerance tests, in the presence of a radiologically normal pituitary fossa. These data support the hypothesis that long-standing hypothalamic stimulation may have been responsible for the later development of a pituitary tumor.
D000172:Acromegaly / Q000209:etiology*; D001971:Bromocriptine / Q000627:therapeutic use; D002648:Child; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000503:physiopathology*; D005359:Fibrous Dysplasia, Polyostotic / Q000097:blood / Q000503:physiopathology*; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007018:Hypopituitarism / Q000209:etiology; D007031:Hypothalamus / Q000503:physiopathology*; D007986:Luteinizing Hormone / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy; D011388:Prolactin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism
D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone